KARL STORZ has acquired ANKLIN, integrating its operations to enhance direct sales and customer engagement in Switzerland's MedTech market.

Information on the Target

The acquisition involves the transfer of all product sales and service operations from ANKLIN, along with approximately 80 employees dedicated to KARL STORZ accounts. This strategic move aims to enhance operational efficiency and maintain high standards of customer service and support.

The transfer was finalized on January 15, 2025. Moving forward, KARL STORZ products in Switzerland will solely be distributed through direct sales under the ANKLIN brand. This change significantly allows KARL STORZ to align more closely with customer needs, particularly concerning the MedTech industry, in which ANKLIN has established a strong market presence.

Industry Overview in Switzerland

The MedTech industry in Switzerland is characterized by its advanced technological framework and highly skilled workforce. Swiss companies are known for producing high-quality medical devices and equi